Ketamine could soon be approved to treat depression


Psychiatrists looking for a new treatment to give patients with major depression and suicidal tendencies may soon be able to administer ketamine inside of their offices.
If ketamine is approved by the Federal Drug Administration as a breakthrough therapy, it will be the first new treatment for a major depressive disorder in about 50 years, CNN reports. On Tuesday, Janssen Pharmaceutical announced it is working on two clinical trials with ketamine — one for treatment-resistant depression and one for depression with suicidal thoughts, and will present the data to the FDA in 2018. Ketamine is also known as the street drug Special K, which gives users the feeling of being out of their body. It was used in the 1960s as an analgesic and sedative and is still on the World Health Organization's Essential Medicine List, but because of its hallucinogenic side effects, it's mostly used today as a veterinary anesthetic.
Depression causes damage to nerves and their transmission pathways, and research leads scientists to believe ketamine remodels those nerves, triggering neuroplastic processes that make new connections among brain cells, Dr. Dan Iosifescu of the Icahn School of Medicine at Mount Sinai in New York City told CNN. "What's unique about ketamine is, this happens in hours or days, while with other depression medications, this happens in weeks to months," he said. Doctors have some concern that using ketamine for depression could reverse a person's tolerance to opioids or lead to substance abuse, and Janssen said its formulation would only be administered by a doctor in their office.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Settling the West Bank: a death knell for a Palestine state?
In the Spotlight The reality on the ground is that the annexation of the West Bank is all but a done deal
-
Sudoku medium: August 23, 2025
The Week's daily medium sudoku puzzle
-
Sudoku hard: August 23, 2025
The Week's daily hard sudoku puzzle
-
Trump halts Gaza visas as Israelis protest war
Speed Read Laura Loomer voiced her concerns over injured Palestinian kids being brought to the US for treatment and a potential 'Islamic invasion'
-
Russia tries Ukraine land grab before Trump summit
Speed Read The incursion may be part of Putin's efforts to boost his bargaining position
-
US, China extend trade war truce for 90 days
Speed Read The triple-digit tariff threat is postponed for another three months
-
Europe counters Putin ahead of Trump summit
Speed Read President Trump will meet with Russian President Vladimir Putin in Alaska this week for Ukraine peace talks
-
Israeli security cabinet OKs Gaza City takeover
Speed Read Netanyahu approved a proposal for Israeli Defense Forces to take over the largest population center in the Gaza Strip
-
How China uses 'dark fleets' to circumvent trade sanctions
The Explainer The fleets are used to smuggle goods like oil and fish
-
Thailand, Cambodia agree to ceasefire in border fight
Speed Read At least 38 people were killed and more than 300,000 displaced in the recent violence
-
Israel 'pauses' Gaza military activity as aid outcry grows
Speed Read The World Health Organization said malnutrition has reached 'alarming levels' in Gaza